Serum adenosine deaminase activity and coronary artery disease: a retrospective case-control study based on 9929 participants

• Main Authors: Chao Xuan, Qing-Wu Tian, Shao-Yan Zhang, Hui Li, Ting-Ting Tian, Peng Zhao, Kang Yue, Yan-Yan Ling, Guo-Wei He, Li-Min Lun
• Format: Article
• Language: English
• Published: SAGE Publishing 2019-12-01
• Series: Therapeutic Advances in Chronic Disease
• Online Access: https://doi.org/10.1177/2040622319891539

Background: Adenosine deaminase (ADA) regulates purine metabolism through the conversion of adenosine to uric acid (UA). Adenosine and UA are closely associated with cardiovascular events, but the correlation between serum ADA activity and coronary artery disease (CAD) has not been defined. Methods: We performed a hospital-based retrospective case-control study that included a total of 5212 patients with CAD and 4717 sex- and age-matched controls. The serum activity of ADA was determined by peroxidase assays in an automatic biochemistry analyzer. Results: Serum ADA activity in the CAD group (10.08 ± 3.57 U/l) was significantly lower than that of the control group (11.71 ± 4.20 U/l, p < 0.001). After adjusting for conventional factors, serum ADA activity negatively correlated with the presence of CAD (odds ratio = 0.852, 95% confidence interval: 0.839–0.865, p  < 0.001). Among the patients with CAD, serum ADA activity was lowest in patients with myocardial infarction (MI; 9.77 ± 3.80 U/l). Diabetes mellitus and hypertension increased the serum ADA activity in CAD patients. Conclusions: Serum ADA activity is significantly attenuated in patients with CAD, particularly in MI. We propose a mechanism by which the body maintains adenosine levels to protect the cardiovascular system in the event of CAD.